1. Scrip
  2. >>New Products

ViiV Readies Entry To HIV PrEP Market After Apretude Approval

 
• By Joseph Haas

A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.

FDA approved background, 3D rendering, blue street sign
ViiV will become the second company into HIV PrEP with approval of Apretude

ViiV Healthcare will enter the HIV pre-exposure prophylaxis (PrEP) market in early 2022 thanks to the US Food and Drug Administration’s approval of a long-acting injectable formulation of cabotegravir, creating direct competition for Gilead Sciences, Inc. in the PrEP space with a differentiated product that ViiV said can improve patient adherence to therapy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

 
• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

Galapagos Chief Exec Stoffels Leaving, While Firm Names Spinout’s CEO

 
• By Mandy Jackson

Paul Stoffels, the J&J research veteran who helmed Galapagos during a crucial period, will retire upon the appointment of a new CEO as the company continues its latest transformation.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.